Tumour mutational burden: clinical utility, challenges and emerging improvements

Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous mutations present within the cancer genome, varies across and within cancer types. A first wave of retrospective and prospective research identified TMB as a predictive biomarker of response to immune-checkpoint in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Budczies, Jan (VerfasserIn) , Kazdal, Daniel (VerfasserIn) , Menzel, Michael (VerfasserIn) , Beck, Susanne (VerfasserIn) , Kluck, Klaus (VerfasserIn) , Altbürger, Christian (VerfasserIn) , Schwab, Constantin (VerfasserIn) , Allgäuer, Michael (VerfasserIn) , Ahadova, Aysel (VerfasserIn) , Kloor, Matthias (VerfasserIn) , Schirmacher, Peter (VerfasserIn) , Peters, Solange (VerfasserIn) , Krämer, Alwin (VerfasserIn) , Christopoulos, Petros (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: October 2024
In: Nature reviews. Clinical oncology
Year: 2024, Jahrgang: 21, Heft: 10, Pages: 725-742
ISSN:1759-4782
DOI:10.1038/s41571-024-00932-9
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41571-024-00932-9
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41571-024-00932-9
Volltext
Verfasserangaben:Jan Budczies, Daniel Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor, Peter Schirmacher, Solange Peters, Alwin Krämer, Petros Christopoulos & Albrecht Stenzinger

MARC

LEADER 00000caa a2200000 c 4500
001 1905694660
003 DE-627
005 20241205181126.0
007 cr uuu---uuuuu
008 241015s2024 xx |||||o 00| ||eng c
024 7 |a 10.1038/s41571-024-00932-9  |2 doi 
035 |a (DE-627)1905694660 
035 |a (DE-599)KXP1905694660 
035 |a (OCoLC)1475315217 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Budczies, Jan  |d 1970-  |e VerfasserIn  |0 (DE-588)124086403  |0 (DE-627)706532724  |0 (DE-576)186167679  |4 aut 
245 1 0 |a Tumour mutational burden  |b clinical utility, challenges and emerging improvements  |c Jan Budczies, Daniel Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor, Peter Schirmacher, Solange Peters, Alwin Krämer, Petros Christopoulos & Albrecht Stenzinger 
264 1 |c October 2024 
300 |b Illustrationen 
300 |a 18 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Zuerst veröffentlicht: 27. August 2024 
500 |a Gesehen am 15.10.2024 
520 |a Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous mutations present within the cancer genome, varies across and within cancer types. A first wave of retrospective and prospective research identified TMB as a predictive biomarker of response to immune-checkpoint inhibitors and culminated in the disease-agnostic approval of pembrolizumab for patients with TMB-high tumours based on data from the Keynote-158 trial. Although the applicability of outcomes from this trial to all cancer types and the optimal thresholds for TMB are yet to be ascertained, research into TMB is advancing along three principal avenues: enhancement of TMB assessments through rigorous quality control measures within the laboratory process, including the mitigation of confounding factors such as limited panel scope and low tumour purity; refinement of the traditional TMB framework through the incorporation of innovative concepts such as clonal, persistent or HLA-corrected TMB, tumour neoantigen load and mutational signatures; and integration of TMB with established and emerging biomarkers such as PD-L1 expression, microsatellite instability, immune gene expression profiles and the tumour immune contexture. Given its pivotal functions in both the pathogenesis of cancer and the ability of the immune system to recognize tumours, a profound comprehension of the foundational principles and the continued evolution of TMB are of paramount relevance for the field of oncology. 
650 4 |a Cancer genetics 
650 4 |a Cancer immunotherapy 
650 4 |a Predictive markers 
650 4 |a Tumour biomarkers 
700 1 |a Kazdal, Daniel  |d 1983-  |e VerfasserIn  |0 (DE-588)114929650X  |0 (DE-627)1009614088  |0 (DE-576)496635867  |4 aut 
700 1 |a Menzel, Michael  |e VerfasserIn  |0 (DE-588)1247100944  |0 (DE-627)1780550677  |4 aut 
700 1 |a Beck, Susanne  |d 1985-  |e VerfasserIn  |0 (DE-588)1164102362  |0 (DE-627)1028488866  |0 (DE-576)508378915  |4 aut 
700 1 |a Kluck, Klaus  |e VerfasserIn  |0 (DE-588)122679940X  |0 (DE-627)1747876127  |4 aut 
700 1 |a Altbürger, Christian  |e VerfasserIn  |0 (DE-588)1242510397  |0 (DE-627)1772430528  |4 aut 
700 1 |a Schwab, Constantin  |d 1992-  |e VerfasserIn  |0 (DE-588)1106892291  |0 (DE-627)863243045  |0 (DE-576)474954269  |4 aut 
700 1 |a Allgäuer, Michael  |e VerfasserIn  |0 (DE-588)1178366790  |0 (DE-627)1049312597  |0 (DE-576)517751453  |4 aut 
700 1 |a Ahadova, Aysel  |d 1988-  |e VerfasserIn  |0 (DE-588)106835268X  |0 (DE-627)820167118  |0 (DE-576)427724783  |4 aut 
700 1 |a Kloor, Matthias  |d 1972-  |e VerfasserIn  |0 (DE-588)124552803  |0 (DE-627)363416609  |0 (DE-576)294228616  |4 aut 
700 1 |a Schirmacher, Peter  |d 1961-  |e VerfasserIn  |0 (DE-588)1020440112  |0 (DE-627)691221197  |0 (DE-576)360427448  |4 aut 
700 1 |a Peters, Solange  |e VerfasserIn  |4 aut 
700 1 |a Krämer, Alwin  |e VerfasserIn  |0 (DE-588)1067780025  |0 (DE-627)819183431  |0 (DE-576)426900820  |4 aut 
700 1 |a Christopoulos, Petros  |d 1977-  |e VerfasserIn  |0 (DE-588)138659702  |0 (DE-627)604886756  |0 (DE-576)308488067  |4 aut 
700 1 |a Stenzinger, Albrecht  |e VerfasserIn  |0 (DE-588)139606106  |0 (DE-627)703395238  |0 (DE-576)312432755  |4 aut 
773 0 8 |i Enthalten in  |t Nature reviews. Clinical oncology  |d New York, NY : Nature Publ. Group, 2009  |g 21(2024), 10 vom: Okt., Seite 725-742  |h Online-Ressource  |w (DE-627)598788506  |w (DE-600)2491414-9  |w (DE-576)327495804  |x 1759-4782  |7 nnas  |a Tumour mutational burden clinical utility, challenges and emerging improvements 
773 1 8 |g volume:21  |g year:2024  |g number:10  |g month:10  |g pages:725-742  |g extent:18  |a Tumour mutational burden clinical utility, challenges and emerging improvements 
856 4 0 |u https://doi.org/10.1038/s41571-024-00932-9  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext  |7 1 
856 4 0 |u https://www.nature.com/articles/s41571-024-00932-9  |x Verlag  |z lizenzpflichtig  |3 Volltext  |7 1 
951 |a AR 
992 |a 20241015 
993 |a Article 
994 |a 2024 
998 |g 139606106  |a Stenzinger, Albrecht  |m 139606106:Stenzinger, Albrecht  |d 910000  |d 912000  |e 910000PS139606106  |e 912000PS139606106  |k 0/910000/  |k 1/910000/912000/  |p 15  |y j 
998 |g 138659702  |a Christopoulos, Petros  |m 138659702:Christopoulos, Petros  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PC138659702  |e 950000PC138659702  |e 950900PC138659702  |e 50000PC138659702  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 14 
998 |g 1067780025  |a Krämer, Alwin  |m 1067780025:Krämer, Alwin  |d 910000  |d 910100  |e 910000PK1067780025  |e 910100PK1067780025  |k 0/910000/  |k 1/910000/910100/  |p 13 
998 |g 1020440112  |a Schirmacher, Peter  |m 1020440112:Schirmacher, Peter  |d 910000  |d 912000  |e 910000PS1020440112  |e 912000PS1020440112  |k 0/910000/  |k 1/910000/912000/  |p 11 
998 |g 124552803  |a Kloor, Matthias  |m 124552803:Kloor, Matthias  |d 910000  |d 912000  |d 50000  |e 910000PK124552803  |e 912000PK124552803  |e 50000PK124552803  |k 0/910000/  |k 1/910000/912000/  |k 0/50000/  |p 10 
998 |g 106835268X  |a Ahadova, Aysel  |m 106835268X:Ahadova, Aysel  |d 910000  |d 912000  |e 910000PA106835268X  |e 912000PA106835268X  |k 0/910000/  |k 1/910000/912000/  |p 9 
998 |g 1178366790  |a Allgäuer, Michael  |m 1178366790:Allgäuer, Michael  |d 910000  |d 912000  |e 910000PA1178366790  |e 912000PA1178366790  |k 0/910000/  |k 1/910000/912000/  |p 8 
998 |g 1106892291  |a Schwab, Constantin  |m 1106892291:Schwab, Constantin  |d 910000  |d 912000  |e 910000PS1106892291  |e 912000PS1106892291  |k 0/910000/  |k 1/910000/912000/  |p 7 
998 |g 1242510397  |a Altbürger, Christian  |m 1242510397:Altbürger, Christian  |d 910000  |d 912000  |e 910000PA1242510397  |e 912000PA1242510397  |k 0/910000/  |k 1/910000/912000/  |p 6 
998 |g 122679940X  |a Kluck, Klaus  |m 122679940X:Kluck, Klaus  |d 910000  |d 912000  |e 910000PK122679940X  |e 912000PK122679940X  |k 0/910000/  |k 1/910000/912000/  |p 5 
998 |g 1164102362  |a Beck, Susanne  |m 1164102362:Beck, Susanne  |d 910000  |d 912000  |e 910000PB1164102362  |e 912000PB1164102362  |k 0/910000/  |k 1/910000/912000/  |p 4 
998 |g 1247100944  |a Menzel, Michael  |m 1247100944:Menzel, Michael  |d 910000  |d 912000  |e 910000PM1247100944  |e 912000PM1247100944  |k 0/910000/  |k 1/910000/912000/  |p 3 
998 |g 114929650X  |a Kazdal, Daniel  |m 114929650X:Kazdal, Daniel  |d 910000  |d 912000  |d 50000  |e 910000PK114929650X  |e 912000PK114929650X  |e 50000PK114929650X  |k 0/910000/  |k 1/910000/912000/  |k 0/50000/  |p 2 
998 |g 124086403  |a Budczies, Jan  |m 124086403:Budczies, Jan  |d 910000  |d 912000  |e 910000PB124086403  |e 912000PB124086403  |k 0/910000/  |k 1/910000/912000/  |p 1  |x j 
999 |a KXP-PPN1905694660  |e 4595279191 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"October 2024"}],"relHost":[{"pubHistory":["6.2009,4 -"],"note":["Gesehen am 09.03.2021"],"part":{"volume":"21","year":"2024","issue":"10","extent":"18","pages":"725-742","text":"21(2024), 10 vom: Okt., Seite 725-742"},"language":["eng"],"titleAlt":[{"title":"Nature reviews / Clinical oncology"}],"disp":"Tumour mutational burden clinical utility, challenges and emerging improvementsNature reviews. Clinical oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"598788506","origin":[{"dateIssuedDisp":"2009-","publisher":"Nature Publ. Group","publisherPlace":"New York, NY","dateIssuedKey":"2009"}],"id":{"zdb":["2491414-9"],"eki":["598788506"],"issn":["1759-4782"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Nature reviews","partname":"Clinical oncology","title":"Nature reviews"}]}],"id":{"eki":["1905694660"],"doi":["10.1038/s41571-024-00932-9"]},"physDesc":[{"extent":"18 S.","noteIll":"Illustrationen"}],"title":[{"title":"Tumour mutational burden","subtitle":"clinical utility, challenges and emerging improvements","title_sort":"Tumour mutational burden"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Zuerst veröffentlicht: 27. August 2024","Gesehen am 15.10.2024"],"recId":"1905694660","person":[{"display":"Budczies, Jan","given":"Jan","role":"aut","family":"Budczies"},{"role":"aut","family":"Kazdal","given":"Daniel","display":"Kazdal, Daniel"},{"given":"Michael","display":"Menzel, Michael","role":"aut","family":"Menzel"},{"display":"Beck, Susanne","given":"Susanne","role":"aut","family":"Beck"},{"family":"Kluck","role":"aut","given":"Klaus","display":"Kluck, Klaus"},{"role":"aut","family":"Altbürger","given":"Christian","display":"Altbürger, Christian"},{"family":"Schwab","role":"aut","display":"Schwab, Constantin","given":"Constantin"},{"display":"Allgäuer, Michael","given":"Michael","family":"Allgäuer","role":"aut"},{"given":"Aysel","display":"Ahadova, Aysel","role":"aut","family":"Ahadova"},{"family":"Kloor","role":"aut","display":"Kloor, Matthias","given":"Matthias"},{"family":"Schirmacher","role":"aut","display":"Schirmacher, Peter","given":"Peter"},{"given":"Solange","display":"Peters, Solange","role":"aut","family":"Peters"},{"given":"Alwin","display":"Krämer, Alwin","family":"Krämer","role":"aut"},{"given":"Petros","display":"Christopoulos, Petros","family":"Christopoulos","role":"aut"},{"family":"Stenzinger","role":"aut","given":"Albrecht","display":"Stenzinger, Albrecht"}],"name":{"displayForm":["Jan Budczies, Daniel Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor, Peter Schirmacher, Solange Peters, Alwin Krämer, Petros Christopoulos & Albrecht Stenzinger"]},"language":["eng"]} 
SRT |a BUDCZIESJATUMOURMUTA2024